Atsuko Katsumoto

Atsuko Katsumoto

Auto-generated profile, based on publicly available information

Atsuko Katsumoto

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AKAtsuko Katsumoto
Atsuko Katsumoto
HLHaiyan Lu
Haiyan Lu
AMAline S. Miranda
Aline S. Miranda
RRRichard M. Ransohoff
Richard M. Ransohoff
Microglia, the only nonneuroepithelial cells found in the parenchyma of the CNS, originate during embryogenesis from the yolk sac and enter the CNS quite early (embryonic day 9.5–10 in mice). Thereafter, microglia are maintained independently of any input from the blood and, in particular, do not require hematopoietic stem cells as a source of replacement for senescent cells. Monocytes are hematopoietic cells, derived from bone marrow. The ontogeny of microglia and monocytes is important for understanding CNS pathologies. Microglial functions are distinct from those of blood-derived monocytes, which invade the CNS only under pathological conditions. Recent data reveal that microglia play an important role in managing neuronal cell death, neurogenesis, and synaptic interactions. In this article, we discuss the physiology of microglia and the functions of monocytes in CNS pathology. We address the roles of microglia and monocytes in neurodegenerative diseases as an example of CNS pathology.

4 October 2013 in neurogenetics
Verified
Journal Article
Closed access
PDF file
COChihiro Ohba
Chihiro Ohba
HOHitoshi Osaka
Hitoshi Osaka
MIMizue Iai
Mizue Iai
SYSumimasa Yamashita
Sumimasa Yamashita
YSYume Suzuki
Yume Suzuki
HSHirotomo Saitsu
Hirotomo Saitsu

1 January 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
AMAmanda Miranda
Amanda Miranda
CZCun-Jin Zhang
Cun-Jin Zhang
AKAtsuko Katsumoto
Atsuko Katsumoto
Antonio TeixeiraAntonio Teixeira
Antonio Teixeira

3 December 2015 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
SGStefka Gyoneva
Stefka Gyoneva
DKDaniel Kim
Daniel Kim
AKAtsuko Katsumoto
Atsuko Katsumoto
OKO. Nicole Kokiko-Cochran
O. Nicole Kokiko-Cochran
BLBruce T. Lamb
Bruce T. Lamb
RRRichard M. Ransohoff
Richard M. Ransohoff
Millions of people experience traumatic brain injury (TBI) as a result of falls, car accidents, sports injury, and blast. TBI has been associated with the development of neurodegenerative conditions such as Alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE). In the initial hours and days, the pathology of TBI comprises neuronal injury, breakdown of the blood–brain barrier, and inflammation. At the cellular level, the inflammatory reaction consists of responses by brain-resident microglia, astrocytes, and vascular elements as well as infiltration of peripheral cells. After TBI, signaling by chemokine (C-C motif) ligand 2 (CCL2) to the chemokine (C-C motif) receptor 2 (CCR2) is a key regulator of brain infiltration by monocytes. We utilized mice with one or both copies of Ccr2 disrupted by red fluorescent protein (RFP, Ccr2 RFP/+ and Ccr2 RFP/RFP ). We subjected these mice to the mild lateral fluid percussion model of TBI and examined several pathological outcomes 3 days later in order to determine the effects of altered monocyte entry into the brain. Ccr2 deletion reduced monocyte infiltration, diminished lesion cavity volume, and lessened axonal damage after mild TBI, but the microglial reaction to the lesion was not affected. We further examined phosphorylation of the microtubule-associated protein tau, which aggregates in brains of people with TBI, AD, and CTE. Surprisingly, Ccr2 deletion was associated with increased tau mislocalization to the cell body in the cortex and hippocampus by tissue staining and increased levels of phosphorylated tau in the hippocampus by Western blot. Disruption of CCR2 enhanced tau pathology and reduced cavity volume in the context of TBI. The data reveal a complex role for CCR2+ monocytes in TBI, as monitored by cavity volume, axonal damage, and tau phosphorylation.

1 January 2018 in Journal of Neurotrauma
Verified
Journal Article
Closed access
OKOlga N. Kokiko-Cochran
Olga N. Kokiko-Cochran
MSMaha Saber
Maha Saber
SPShweta Puntambekar
Shweta Puntambekar
SBShane Michael Bemiller
Shane Michael Bemiller
AKAtsuko Katsumoto
Atsuko Katsumoto
BLBruce T. Lamb
Bruce T. Lamb
TBI induces widespread neuroinflammation and accumulation of microtubule associated protein tau (MAPT) - two key pathological features of tauopathies. This study sought to characterize the microglial/macrophage response to TBI in genomic-based MAPT transgenic mice in a Mapt knockout background (called hTau). Two-month-old hTau and age-matched control male and female mice received a single lateral fluid percussion TBI or sham injury. Separate groups of mice were aged to an acute (3 days post-injury [DPI]) or chronic (135 DPI) post-injury time point. As judged by tissue immunostaining for macrophage markers, microglial/macrophage response to TBI was enhanced at 3 DPI in hTau mice compared to control TBI and sham mice. However, MAPT phosphorylation increased in hTau mice regardless of injury group. Flow cytometric analysis revealed distinct populations of microglia and macrophages within all groups at 135 DPI. Unexpectedly, microglial reactivity was significantly reduced in hTau TBI mice compared to all other groups. Instead, hTau TBI mice showed a persistent macrophage response. In addition, TBI enhanced MAPT pathology in the temporal cortex and hippocampus of hTau TBI mice compared to controls 135 DPI. A battery of behavioral test revealed that TBI in hTau mice resulted in compromised use of spatial search strategies to complete a water maze task despite lack of motor or visual deficits. Collectively, these data indicate that the presence of wild-type human tau alters the microglial/macrophage response to a single TBI, induces delayed, region-specific MAPT pathology, and alters cognitive recovery; however, the causal relationship between these events remains unclear. These results highlight the potential significance of communication between MAPT and microglia/macrophages following TBI and emphasize the role of neuroinflammation in post-injury recovery.

30 January 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
AKAtsuko Katsumoto
Atsuko Katsumoto
AMAmanda Miranda
Amanda Miranda
OBOleg Butovsky
Oleg Butovsky
Antonio TeixeiraAntonio Teixeira
Antonio Teixeira
RRRichard M. Ransohoff
Richard M. Ransohoff
BLBruce T. Lamb
Bruce T. Lamb
Traumatic brain injury (TBI) is a critical public health and socio-economic problem worldwide. A growing body of evidence supports the involvement of inflammatory events in TBI. It has been reported that resident microglia and infiltrating monocytes promote an inflammatory reaction that leads to neuronal death and eventually behavioral and cognitive impairment. Currently, there is no effective treatment for TBI and the development of new therapeutic strategies is a scientific goal of highest priority. Laquinimod, an orally administered neuroimmunomodulator initially developed for the treatment of multiple sclerosis, might be a promising neuroprotective therapy for TBI. Herein, we aim to investigate the hypothesis that laquinimod will reduce the central nervous system (CNS) damage caused by TBI. To test our hypothesis, Ccr2rfp/+ Cx3cr1 gfp/+ mice were submitted to a moderate TBI induced by fluid percussion. Sham controls were submitted only to craniotomy. Mice were treated daily by oral gavage with laquinimod (25 mg/kg) 7 days before and 3 days after TBI. The brains of mice treated or not treated with laquinimod were collected at 3 and 120 days post injury, and brain morphological changes, axonal injury, and neurogenesis were evaluated by microscopy analysis. We also isolated microglia from infiltrating monocytes, and the expression of immune gene mRNAs were analyzed by employing a quantitative NanoString nCounter technique. Laquinimod prevented ventricle enlargement caused by TBI in the long term. Immunohistochemical analyses revealed decreased axonal damage and restored neurogenesis in the laquinimod-treated TBI group at early stage (3 days post injury). Notably, laquinimod inhibited the monocytes infiltration to the brain. Hierarchial clustering demonstrated that the microglial gene expression from the TBI group treated with laquinimod resembles the sham group more than the TBI-water control group. Administration of laquinimod reduced lesion volume and axonal damage and restored neurogenesis after TBI. Laquinimod might be a potential therapy strategy to improve TBI long-term prognosis.